OTLK Share Price | Outlook Therapeutics, Inc. Stock Analysis & Recommendation

Q: What does Outlook Therapeutics, Inc. do?

Overview: Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing biosimilar therapeutics, particularly monoclonal antibodies, in the immunology and oncology sectors. The company operates within the Pharmaceuticals & Biotechnology industry and has a market cap of USD 72.42 Million.Financial Snapshot: Most recent Net Profit: -46 Million (Quarterly Results - Mar 2025) Market cap: USD 72.42 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.79 Return on Equity: 233.83% Price to Book: -2.23Contact Details: Address: 4260 U.S. Route 1, MONMOUTH JUNCTION NJ : 08852 Tel: ['1 609 6193990', '1 212 9152568'] Website: http://oncobiologics.com/

Q: Is Outlook Therapeutics, Inc. overvalued or undervalued?

As of 14 August 2025, the valuation grade for Outlook Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant deterioration in its perceived value. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -2.51 and an EV to EBITDA of -1.40. Additionally, the EV to Capital Employed ratio stands at -15.46, further highlighting the company's financial challenges.In comparison to its peers, Outlook Therapeutics, Inc. has a less favorable position, with ADC Therapeutics SA showing a more negative P/E of -2.4050 and Kinnate Biopharma, Inc. being rated fair with an EV to EBITDA of 0.2381. The company's stock performance has been notably poor, with a 1-year return of -83.31% compared to the S&P 500's positive return of 17.14%, reinforcing the notion that the stock is currently overvalued.

Q: Is Outlook Therapeutics, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Outlook Therapeutics, Inc. has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across various indicators. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish trend. The RSI indicates no signal on the weekly timeframe but is bullish on the monthly. Moving averages are mildly bullish on the daily, but Bollinger Bands are bearish on the weekly and mildly bearish on the monthly. KST is mildly bearish weekly and bearish monthly, and there are no trends indicated by Dow Theory or OBV.In terms of performance, the stock has significantly underperformed compared to the S&P 500 across all periods, with a 1-year return of -83.31% versus the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

885.25 k

Shareholding (Dec 2025)

FII

4.89%

Held by 25 FIIs

DII

90.05%

Held by 6 DIIs

Promoter

0.00%

How big is Outlook Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Outlook Therapeutics, Inc. has a market capitalization of 72.42 million and reported net sales of 0.00 million with a net profit of 21.12 million over the latest four quarters. As of Sep 24, the company has shareholder's funds of -73.08 million and total assets of 28.82 million.

View full answer

What does Outlook Therapeutics, Inc. do?

22-Jun-2025

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing biosimilar therapeutics, particularly monoclonal antibodies, in immunology and oncology. It has a market cap of USD 72.42 million and reported a net profit loss of USD 46 million as of March 2025.

View full answer

Who are in the management team of Outlook Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Outlook Therapeutics, Inc. includes Executive Chairman Randy Thurman, CEO Lawrence Kenyon, and Directors Gerd Auffarth, Julian Gangolli, Andong Huang, Yezan Haddadin, and Kurt Hilzinger. Kenyon holds multiple key executive roles, including President and CFO.

View full answer

Is Outlook Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of August 14, 2025, Outlook Therapeutics, Inc. is rated as risky due to negative valuation ratios and poor stock performance, indicating it is overvalued compared to its peers.

View full answer

Is Outlook Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Outlook Therapeutics, Inc. shows a neutral technical trend with mixed signals, including a bearish weekly MACD and a significant 1-year return of -83.31%, underperforming the S&P 500's 17.14%.

View full answer

Compare Outlook Therapeutics, Inc. with Similar Stocks

Clene, Inc.Immunic, Inc.Veru, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 29 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.73

Return on Equity

164.44%

Price to Book

-0.76

Revenue and Profits:

Net Sales:

-1 Million

(Quarterly Results - Dec 2025)

Net Profit:

-23 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-88.63%

6 Months

-78.96%

1 Year

-86.09%

2 Years

-97.59%

3 Years

-79.81%

4 Years

-99.48%

5 Years

-99.54%

Outlook Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

5.39%

EBIT Growth (5y)

-28.12%

EBIT to Interest (avg)

-23.56

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.79

Sales to Capital Employed (avg)

-0.36

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

29.30%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.76

EV to EBIT

-0.91

EV to EBITDA

-0.91

EV to Capital Employed

-5.45

EV to Sales

57.27

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 12 Schemes (5.06%)

Foreign Institutions

Held by 25 Foreign Institutions (4.89%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -232.76% vs 255.36% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "-1.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-13.50",
          "val2": "-21.60",
          "chgp": "37.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.50",
          "val2": "39.00",
          "chgp": "-124.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-23.10",
          "val2": "17.40",
          "chgp": "-232.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2025 is 17.24% vs -27.80% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-66.90",
          "val2": "-71.60",
          "chgp": "6.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "3.20",
          "chgp": "-90.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "3.40",
          "val2": "-1.30",
          "chgp": "361.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.40",
          "val2": "-75.40",
          "chgp": "17.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-47,442.50%",
          "val2": "0.00%",
          "chgp": "-4,744.25%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

-1.20

0.00

Operating Profit (PBDIT) excl Other Income

-13.50

-21.60

37.50%

Interest

0.00

Exceptional Items

-9.50

39.00

-124.36%

Consolidate Net Profit

-23.10

17.40

-232.76%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -232.76% vs 255.36% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

1.40

0.00

Operating Profit (PBDIT) excl Other Income

-66.90

-71.60

6.56%

Interest

0.30

3.20

-90.63%

Exceptional Items

3.40

-1.30

361.54%

Consolidate Net Profit

-62.40

-75.40

17.24%

Operating Profit Margin (Excl OI)

-47,442.50%

0.00%

-4,744.25%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in year ended Sep 2025 is 17.24% vs -27.80% in Sep 2024

All Annual Results

Company CV

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Outlook Therapeutics, Inc., formerly Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab.

Company Coordinates

Company Details

4260 U.S. Route 1 , MONMOUTH JUNCTION NJ : 08852

Tel: 1 609 61939901 212 9152568

http://oncobiologics.com/

Registrar Details